resident Trump’s Food and Drug Administration may not be as lax as the drug industry hoped. The agency rejected a debatably effective treatment for muscular dystrophy Wednesday, signaling that its self-professed openness to approving new drugs has limitations.

The drug, developed by PTC Therapeutics (PTCT), was meant to treat the rare disease Duchenne muscular dystrophy, but failed to differentiate itself from placebo in two clinical trials.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.